Delivery Order SPE2DB22D2211-SPE2DB25FSAVV
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,186.32 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500 count) on September 2, 2025, with completion scheduled for September 3, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed under AmerisourceBergen's broader indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical supply will be delivered to the...
- The Defense Logistics Agency (DLA) awarded a $11,073.06 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ondansetron HCl 4 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 10, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,413.35 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (30-count) on July 18, 2025, with an ultimate completion date of July 21, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performs this work at its corporate office location. The...
- The Defense Logistics Agency awarded a delivery order valued at $14,466.96 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ondansetron HCL 4 mg tablets in quantities of 30. The contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,537.96 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (30-count) with an ultimate completion date of October 22, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 tablets) with a ceiling value of $5,367.10. This is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. The product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 30 units. This order, valued at $14,531.95, represents a competitive firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,923.09 to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 30. The contract is a firm fixed price delivery order with no set-aside designation, indicating competitive award, and carries an ultimate completion date of June 27, 2025. Performance will be executed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,255.21 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (30-count units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This firm fixed-price delivery order was competitively awarded without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $2,931.30 to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Ondansetron HCl 4 mg tablets (500 count). The contract, which is of the firm fixed-price delivery order type with no set-aside designation, represents a competitive award to the pharmaceutical distributor. Performance of this order is scheduled for completion by July 15, 2025, and will be executed at the awardee's corporate office location in...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSAVVDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,724.62 to AmerisourceBergen Drug Corp for Ondansetron HCL 4 mg tablets (30-count) on July 15, 2025, with an ultimate completion date of July 16, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through DLA's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Ondansetron, an antiemetic medication commonly used in medical settings, represents one of many pharmaceutical commodities available under this contract vehicle, which encompasses specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 7/15/25 |